Low-Dose Naltrexone For ME/CFS: Dose-Finding
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Alabama at Birmingham
About this trial
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Eligibility criteria
Qualifiers
Between ages of 18 and 65
Living in Alabama
Meets ME-ICC criteria
Disqualifiers
Abnormal hepatic function
Abnormal renal function
Abnormal complete blood count
Evidence of active or chronic systemic infection
Trial design
Treatments tested in this trial
- Low-Dose Naltrexone, 1.5mg
- Low-Dose Naltrexone, 3.0mg
- Low-Dose Naltrexone, 4.5mg
- Low-Dose Naltrexone, 6.0mg
Treatment groups
75 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov